Calcium channel blockers reduce oxaliplatin-induced acute neuropathy: A retrospective study of 69 male patients receiving modified FOLFOX6 therapy

Yoko Tatsushima, Nobuaki Egashira, Yuri Narishige, Shiori Fukui, takehiro kawashiri, Yui Yamauchi, Ryozo Oishi

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Oxaliplatin-based chemotherapy has been widely used for colorectal cancer. However, it causes severe acute and chronic peripheral neuropathies. Recently, we reported that calcium channel blockers prevent the oxaliplatin-induced cold hyperalgesia in rats. The purpose of this study was to determine whether the treatment with calcium channel blockers prevents the peripheral neuropathy during oxaliplatin therapy. The electronic medical charts for patients who received modified FOLFOX6 regimen from January 2008 to December 2010 were evaluated. Of the 200 patients who received modified FOLFOX6 therapy, 84 patients were excluded due to the exclusion criteria. Calcium channel blockers had been taken by 26 of 69 male patients, but only three of 47 female patients. Therefore, in the present analysis, the male data of the groups with and without calcium channel blockers (n= 26 and 43, respectively) were compared. The cumulative incidence curve of acute neuropathy was significantly lower in the group with calcium channel blockers (P= 0.0438, log-rank test), whereas there was no difference between these groups in the cumulative incidence curve of chronic neuropathy (P= 0.4919, log-rank test). The present study indicated that calcium channel blockers inhibit the development of acute peripheral neuropathy in patients receiving modified FOLFOX6 therapy.

Original languageEnglish
Pages (from-to)39-42
Number of pages4
JournalBiomedicine and Pharmacotherapy
Volume67
Issue number1
DOIs
Publication statusPublished - Feb 1 2013

Fingerprint

oxaliplatin
Calcium Channel Blockers
Retrospective Studies
Peripheral Nervous System Diseases
Therapeutics
Medical Electronics
Hyperalgesia
Incidence
Colorectal Neoplasms

All Science Journal Classification (ASJC) codes

  • Pharmacology

Cite this

Calcium channel blockers reduce oxaliplatin-induced acute neuropathy : A retrospective study of 69 male patients receiving modified FOLFOX6 therapy. / Tatsushima, Yoko; Egashira, Nobuaki; Narishige, Yuri; Fukui, Shiori; kawashiri, takehiro; Yamauchi, Yui; Oishi, Ryozo.

In: Biomedicine and Pharmacotherapy, Vol. 67, No. 1, 01.02.2013, p. 39-42.

Research output: Contribution to journalArticle

@article{a187ca41bd534abb8ee0ac3b8720679b,
title = "Calcium channel blockers reduce oxaliplatin-induced acute neuropathy: A retrospective study of 69 male patients receiving modified FOLFOX6 therapy",
abstract = "Oxaliplatin-based chemotherapy has been widely used for colorectal cancer. However, it causes severe acute and chronic peripheral neuropathies. Recently, we reported that calcium channel blockers prevent the oxaliplatin-induced cold hyperalgesia in rats. The purpose of this study was to determine whether the treatment with calcium channel blockers prevents the peripheral neuropathy during oxaliplatin therapy. The electronic medical charts for patients who received modified FOLFOX6 regimen from January 2008 to December 2010 were evaluated. Of the 200 patients who received modified FOLFOX6 therapy, 84 patients were excluded due to the exclusion criteria. Calcium channel blockers had been taken by 26 of 69 male patients, but only three of 47 female patients. Therefore, in the present analysis, the male data of the groups with and without calcium channel blockers (n= 26 and 43, respectively) were compared. The cumulative incidence curve of acute neuropathy was significantly lower in the group with calcium channel blockers (P= 0.0438, log-rank test), whereas there was no difference between these groups in the cumulative incidence curve of chronic neuropathy (P= 0.4919, log-rank test). The present study indicated that calcium channel blockers inhibit the development of acute peripheral neuropathy in patients receiving modified FOLFOX6 therapy.",
author = "Yoko Tatsushima and Nobuaki Egashira and Yuri Narishige and Shiori Fukui and takehiro kawashiri and Yui Yamauchi and Ryozo Oishi",
year = "2013",
month = "2",
day = "1",
doi = "10.1016/j.biopha.2012.10.006",
language = "English",
volume = "67",
pages = "39--42",
journal = "Biomedicine and Pharmacotherapy",
issn = "0753-3322",
publisher = "Elsevier Masson",
number = "1",

}

TY - JOUR

T1 - Calcium channel blockers reduce oxaliplatin-induced acute neuropathy

T2 - A retrospective study of 69 male patients receiving modified FOLFOX6 therapy

AU - Tatsushima, Yoko

AU - Egashira, Nobuaki

AU - Narishige, Yuri

AU - Fukui, Shiori

AU - kawashiri, takehiro

AU - Yamauchi, Yui

AU - Oishi, Ryozo

PY - 2013/2/1

Y1 - 2013/2/1

N2 - Oxaliplatin-based chemotherapy has been widely used for colorectal cancer. However, it causes severe acute and chronic peripheral neuropathies. Recently, we reported that calcium channel blockers prevent the oxaliplatin-induced cold hyperalgesia in rats. The purpose of this study was to determine whether the treatment with calcium channel blockers prevents the peripheral neuropathy during oxaliplatin therapy. The electronic medical charts for patients who received modified FOLFOX6 regimen from January 2008 to December 2010 were evaluated. Of the 200 patients who received modified FOLFOX6 therapy, 84 patients were excluded due to the exclusion criteria. Calcium channel blockers had been taken by 26 of 69 male patients, but only three of 47 female patients. Therefore, in the present analysis, the male data of the groups with and without calcium channel blockers (n= 26 and 43, respectively) were compared. The cumulative incidence curve of acute neuropathy was significantly lower in the group with calcium channel blockers (P= 0.0438, log-rank test), whereas there was no difference between these groups in the cumulative incidence curve of chronic neuropathy (P= 0.4919, log-rank test). The present study indicated that calcium channel blockers inhibit the development of acute peripheral neuropathy in patients receiving modified FOLFOX6 therapy.

AB - Oxaliplatin-based chemotherapy has been widely used for colorectal cancer. However, it causes severe acute and chronic peripheral neuropathies. Recently, we reported that calcium channel blockers prevent the oxaliplatin-induced cold hyperalgesia in rats. The purpose of this study was to determine whether the treatment with calcium channel blockers prevents the peripheral neuropathy during oxaliplatin therapy. The electronic medical charts for patients who received modified FOLFOX6 regimen from January 2008 to December 2010 were evaluated. Of the 200 patients who received modified FOLFOX6 therapy, 84 patients were excluded due to the exclusion criteria. Calcium channel blockers had been taken by 26 of 69 male patients, but only three of 47 female patients. Therefore, in the present analysis, the male data of the groups with and without calcium channel blockers (n= 26 and 43, respectively) were compared. The cumulative incidence curve of acute neuropathy was significantly lower in the group with calcium channel blockers (P= 0.0438, log-rank test), whereas there was no difference between these groups in the cumulative incidence curve of chronic neuropathy (P= 0.4919, log-rank test). The present study indicated that calcium channel blockers inhibit the development of acute peripheral neuropathy in patients receiving modified FOLFOX6 therapy.

UR - http://www.scopus.com/inward/record.url?scp=84873078761&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873078761&partnerID=8YFLogxK

U2 - 10.1016/j.biopha.2012.10.006

DO - 10.1016/j.biopha.2012.10.006

M3 - Article

C2 - 23206755

AN - SCOPUS:84873078761

VL - 67

SP - 39

EP - 42

JO - Biomedicine and Pharmacotherapy

JF - Biomedicine and Pharmacotherapy

SN - 0753-3322

IS - 1

ER -